Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 34.40% | 72.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.58% | 12.51% | |||
| Operating Income | -13.58% | -12.51% | |||
| Income Before Tax | -11.46% | 86.18% | |||
| Income Tax Expenses | 507.14% | -4.55% | |||
| Earnings from Continuing Operations | -12.21% | 86.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.21% | 86.16% | |||
| EBIT | -13.58% | -12.51% | |||
| EBITDA | -13.58% | -12.51% | |||
| EPS Basic | 0.23% | 99.71% | |||
| Normalized Basic EPS | 38.39% | 95.39% | |||
| EPS Diluted | 0.23% | 99.71% | |||
| Normalized Diluted EPS | 38.39% | 95.39% | |||
| Average Basic Shares Outstanding | 80.91% | 2,182.00% | |||
| Average Diluted Shares Outstanding | 80.91% | 2,182.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||